Pressmeddelanden

REG MAR
PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES PILA PHARMA AB (publ) (FN STO: PILA) today informs the continuation of preparations for the clinical trial application for PP-CT03, a pivotal and pioneering 12-week Phase 2a stud...
REG
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025 PILA PHARMA AB (publ) höll på torsdagen den 29 april 2025 årsstämma hos MAQS Advokatbyrå, Gibraltargatan 7 i Malmö. Följande huvudsakliga beslut fattades:Fastställande av resulta...
PILA PHARMA UPCOMING INVESTOR MEETINGS PILA PHARMA AB (publ) (FN STO: PILA) hereby invites investors and others with interest in the Company, to meet PILA PHARMA at these upcoming events: Malmömo­rgon (Slagthuset, Mal...
PILA PHARMA: REMINDER - LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING PILA PHARMA AB (publ) (FN STO: PILA) today reminds shareholders that today, 23 April is the last day to register attendance at this year's Annual General meeting. PILA PHARMA wel...
REG
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdag den 29 april 2025, kl. 15.00 i MAQS Advokatbyrås loka...
REG
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024 PILA PHARMA AB (publ) (FN STO: PILA) announces that the annual report (in Swedish) is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-informa...
Visa fler pressmeddelanden

Rapporter

Datum Rubrik
Annual Report 2024
Year-end report 2024
Interim report 1 January - 30 June 2024

Video

Finansiell kalender

Halvårsrapport 2025 Delårsrapport

Om PILA PHARMA

Prenumerera

Få löpande information från PILA PHARMA via e-post.

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn PILA ISIN-kod SE0015988274 Certified Adviser Aqurat Fondkommission